APG Asset Management N.V. Has $1.47 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

APG Asset Management N.V. reduced its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 48.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 68,894 shares of the company's stock after selling 64,301 shares during the quarter. APG Asset Management N.V.'s holdings in Teva Pharmaceutical Industries were worth $1,466,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of TEVA. Stifel Financial Corp raised its stake in shares of Teva Pharmaceutical Industries by 54.0% in the third quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock valued at $1,196,000 after purchasing an additional 23,283 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its holdings in Teva Pharmaceutical Industries by 7.2% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock valued at $10,983,000 after buying an additional 33,277 shares during the period. Pinnbrook Capital Management LP acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $4,966,000. Asset Management One Co. Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 14.6% during the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock worth $10,414,000 after acquiring an additional 58,413 shares during the period. Finally, CWA Asset Management Group LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at about $3,340,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock traded up $0.24 during midday trading on Thursday, reaching $13.67. The company had a trading volume of 3,912,735 shares, compared to its average volume of 9,868,582. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The stock has a fifty day simple moving average of $15.57 and a 200 day simple moving average of $17.73. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80. The company has a market capitalization of $15.49 billion, a price-to-earnings ratio of -9.40, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on TEVA. Barclays cut their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. Bank of America cut their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. UBS Group decreased their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. StockNews.com cut shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Monday. Finally, Piper Sandler boosted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.